India's Ranbaxy gets US okay for antihistamine tablets
April 12 |
April 12 (Reuters) - India's Ranbaxy Laboratories Ltd. (RANB.BO) said it got U.S. Food and Drug Administration approval to market Loratadine antihistamine tablets.
Ranbaxy's Loratadine tablets are bioequivalent to Claritin Reditabs of Schering Plough Healthcare Products, the U.S. over-the-counter and consumer products business unit of Schering-Plough Corp. SGP.N. (Reporting by Rakesh Sharma in Bangalore)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters